|
BUB3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.42840000833178E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.55260000095959E-08 |
| Normal-vs-Stage2 |
1.51642999999257E-05 |
| Normal-vs-Stage3 |
3.52360000066554E-08 |
| Normal-vs-Stage4 |
5.50699999999349E-05 |
| Stage1-vs-Stage2 |
2.468800E-01 |
| Stage1-vs-Stage3 |
2.249000E-01 |
| Stage1-vs-Stage4 |
9.292800E-01 |
| Stage2-vs-Stage3 |
8.169400E-01 |
| Stage2-vs-Stage4 |
3.803400E-01 |
| Stage3-vs-Stage4 |
4.423200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.96769994637225E-09 |
| Normal-vs-AfricanAmerican |
6.222400E-03 |
| Normal-vs-Asian |
1.020410E-03 |
| Caucasian-vs-AfricanAmerican |
3.953800E-01 |
| Caucasian-vs-Asian |
2.844400E-01 |
| AfricanAmerican-vs-Asian |
9.633800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.71889999800845E-08 |
| Normal-vs-Female |
1.22929999513133E-08 |
| Male-vs-Female |
5.391200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.29080000005533E-06 |
| Normal-vs-Age(41-60Yrs) |
1.0666999505915E-09 |
| Normal-vs-Age(61-80Yrs) |
1.35710000015443E-07 |
| Normal-vs-Age(81-100Yrs) |
2.292000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.958300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.306600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.155600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.765000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.577220E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.855780E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.094600E-01 |
| Classical-VS-Follicular |
6.723400E-03 |
| Classical-VS-Other |
7.600400E-01 |
| Classical-VS-Normal |
1.96343999999682E-05 |
| Tall-VS-Follicular |
2.382400E-01 |
| Tall-VS-Other |
9.789400E-01 |
| Tall-VS-Normal |
5.315800E-03 |
| Follicular-VS-Other |
5.361600E-01 |
| Follicular-VS-Normal |
4.37389999774496E-08 |
| Other-VS-Normal |
4.511700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.57390014751979E-10 |
| Normal-vs-N1 |
1.52517999999491E-05 |
| N0-vs-N1 |
9.536800E-01 |
|
|
